Arrowhead Pharmaceuticals (ARWR) is back in focus after Australia’s Therapeutic Goods Administration approved REDEMPLO (plozasiran) to treat adults with familial chylomicronemia syndrome, extending the drug’s reach beyond the United States, Canada, and China.

Those regulatory wins appear to be reflected in the share price, with a 25.17% 1 month share price return and a 12.69% year to date share price return, alongside a 1 year total shareholder return of 446.42%.

If REDEMPLO’s progress has you thinking about other RNA and AI driven healthcare stories, it could be worth scanning 33 healthcare AI stocks

With Arrowhead now trading at $76.39, sitting about 11% below the average analyst price target and at a reported intrinsic discount of just over 50%, investors may question whether there is still a buying opportunity or whether the market is already pricing in future growth.

Most Popular Narrative: 19.2% Overvalued

Compared with Arrowhead Pharmaceuticals’ last close at $76.39, the most followed narrative points to a fair value of $64.08, implying the share price sits ahead of that estimate while still reflecting a sizeable growth story.

Analysts have raised their price targets on Arrowhead Pharmaceuticals by roughly $6 to the mid $40s to low $60s range, citing the FDA approval of Redemplo, a strengthened commercial outlook in familial chylomicronemia syndrome and sHTG, and underappreciated long term cost and margin advantages.

Want to see what is baked into that premium tag? Revenue trajectories, margin shifts and a punchy future earnings multiple all sit at the core of this story.

Result: Fair Value of $64.08 (OVERVALUED)

However, still keep in mind that delays or setbacks in plozasiran and zodasiran trials, or weaker than expected partner milestone payments, could quickly challenge this premium story.

Another View: Cash Flows Tell a Different Story

Analysts see Arrowhead as roughly 19% overvalued at $76.39 versus a fair value of $64.08. Our DCF model, however, points in the opposite direction, with the stock trading about 51% below an estimated future cash flow value of $156.65. Which set of assumptions do you find more realistic for the long haul?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Arrowhead Pharmaceuticals for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 48 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly divided, it makes sense to look at the same data and decide what feels realistic for your own risk tolerance and time frame. To see what the market is optimistic about right now, check out the 2 key rewards.

Ready for more investment ideas?

If you stop with Arrowhead, you miss a wider field of opportunities, so take a few minutes to compare it with other stocks using focused screeners.

• Spot potential value opportunities quickly by scanning 48 high quality undervalued stocks that combine quality fundamentals with discounted prices.
• Prioritise resilience by reviewing 70 resilient stocks with low risk scores that align better with a cautious, capital preservation mindset.
• Hunt for underfollowed opportunities by checking the screener containing 25 high quality undiscovered gems that may not yet be widely on investors’ radars.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.